Page 4 - Jeffreyl Tate News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Jeffreyl tate. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Jeffreyl Tate Today - Breaking & Trending Today

Cyclo Therapeutics Announces Positive Efficacy Data from Extension Protocol with Trappsol Cyclo in Patients with Niemann-Pick Disease Type C

Posted on
312
Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) (NasdaqCM:CYTHW), a clinical stage biotechnology company developing a cyclodextrin platform for the treatment of neurodegenerative diseases, including its lead candidate Trappsol
® Cyclo™ for the treatment of Niemann-Pick Disease Type C (NPC), today announced initial data from its “Open-Label Study of Long-Term Safety and Efficacy of Intravenous Trappsol
® Cyclo™ (HPBCD) in Niemann-Pick Disease Type C,” NCT03893071. Eight patients living in the US who completed the Phase I trial (NCT02939547) were eligible for the extension program. All eight enrolled.
The first patient was dosed in the Open-Label extension study in May 2019 and the last patient enrolled was in February 2020. The initial efficacy results presented below have a data cut-off of September 2020. ....

University Of Cincinnati , United States , Loren Pena , Jeffreyl Tate , Caroline Hastings , Benny Liu , Exchange Commission , Cyclo Therapeutics Inc , Department Of Pediatrics , Division Of Human Genetics , University Of Cincinnati College Medicine , Cyclo Therapeutics , Label Study , Long Term Safety , Open Label Study , Hospital Oakland , Associate Professor , Cincinnati College , Attending Physician , Human Genetics , Cincinnati Children , Expanded Access , Harbor Statement , Media Contact , பல்கலைக்கழகம் ஆஃப் ஸிந்ஸந்யாடீ , ஒன்றுபட்டது மாநிலங்களில் ,